Multiple sclerosis biomarkers

Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers

Retrieved on: 
Tuesday, July 6, 2021
Oncology, Health, Medical devices, Genetics, Research, Science, Biotechnology, Branches of biology, Biology, Biomarkers, Life sciences, Biotechnology, Molecular biology, Laboratory techniques, Cancer biomarker, Polymerase chain reaction, Multiple sclerosis biomarkers, Digital polymerase chain reaction

This is the fourth issued patent for the technology, which identifies rare cancer biomarkers found in tissue, blood, and cerebrospinal fluid (CSF).

Key Points: 
  • This is the fourth issued patent for the technology, which identifies rare cancer biomarkers found in tissue, blood, and cerebrospinal fluid (CSF).
  • It can be used to enhance the performance and specificity of the PCR method, the most widely used amplification approach for research and clinical diagnostic applications.
  • Our strong and growing intellectual property portfolio enables Biocept to develop and commercialize our highly differentiated technologies and testing services.
  • This includes worldwide patent protection on its highly sensitive methods for detecting cancer biomarkers that are used by physicians for treatment decisions.

Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease

Retrieved on: 
Tuesday, October 27, 2020
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Biology, Alzheimer's disease, Clinical medicine, Biomarkers, Apolipoprotein E, Cerebral atrophy, Amyloid, Multiple sclerosis biomarkers, Alzheimer's Disease Neuroimaging Initiative, ALZ-801, Alzheon

The biomarkers selected for this study have been shown to correlate with clinical benefit in AD patients in trials with amyloid-targeted antibody therapies.

Key Points: 
  • The biomarkers selected for this study have been shown to correlate with clinical benefit in AD patients in trials with amyloid-targeted antibody therapies.
  • This Phase 2 study is the first AD biomarker trial to prospectively evaluate APOE4 carriers using leading-edge cerebrospinal fluid (CSF) and plasma biomarkers, as well as volumetric magnetic resonance imaging (MRI) evaluating brain atrophy.
  • Furthermore, APOE4 carriers have been shown to have up to three-fold higher brain levels of soluble amyloid oligomers compared to non-carriers.
  • This biomarker study is a key element of our overall Alzheimers clinical development program for ALZ801, said Susan Abushakra, MD, Alzheon Chief Medical Officer.

World Cancer Day: Diaceutics Finds Patients Face Delays Getting Potentially Lifesaving Biomarker Tests

Retrieved on: 
Monday, February 4, 2019
Health, Biotechnology, Medical devices, Oncology, Pharmaceutical, Research, Science, Medicine, Biomarkers, Biology, Cancer, Genetic testing, Cancer biomarker, Multiple sclerosis biomarkers

New research from Diaceutics has found that cancer patients are facing delays in getting biomarker tests which, if conducted early and efficiently, can determine patients eligibility for more targeted and potentially lifesaving treatments.

Key Points: 
  • New research from Diaceutics has found that cancer patients are facing delays in getting biomarker tests which, if conducted early and efficiently, can determine patients eligibility for more targeted and potentially lifesaving treatments.
  • The research also found that 63% of cancer patients found the concept of biomarkers, mutations and genetic tests more difficult to understand than information about diagnosis and tests, treatments, risk factors and treatment side effects.
  • However, there is an eagerness among cancer patients to learn more 70% said they would like to know more about biomarkers, mutations and genetic tests above all other topics.
  • Peter Keeling said: This years World Cancer Day highlights the need for early diagnosis and screening something that we are very passionate about at Diaceutics.

Diaceutics Research Finds Cancer Patients Face Delays Getting Potentially Lifesaving Biomarker Tests

Retrieved on: 
Monday, February 4, 2019
Technology, Data management, Health, Biotechnology, Oncology, Professional services, Consulting, Medicine, Biomarkers, Clinical medicine, Branches of biology, Cancer, Cancer biomarker, Multiple sclerosis biomarkers

New research from Diaceutics has found that cancer patients are facing delays in getting biomarker tests which, if conducted early and efficiently, can determine patients eligibility for more targeted and potentially lifesaving treatments.

Key Points: 
  • New research from Diaceutics has found that cancer patients are facing delays in getting biomarker tests which, if conducted early and efficiently, can determine patients eligibility for more targeted and potentially lifesaving treatments.
  • The research also found that 63% of cancer patients found the concept of biomarkers, mutations and genetic tests more difficult to understand than information about diagnosis and tests, treatments, risk factors and treatment side effects.
  • However, there is an eagerness among cancer patients to learn more 70% said they would like to know more about biomarkers, mutations and genetic tests above all other topics.
  • We carried out research previously that found that 156,000 cancer patients in the US and Europe could be missing out on lifesaving drugs every year because of suboptimal diagnostic testing.